Publishing Date: January 2018
Report ID: CH 181143
McAbs has high targeting ability and can directly reach the diseased cells. Now McAbs are widely used in clinical practice with the unique advantages of reducing the damage of normal cells side effects.
The market share monoclonal antibody in global biopharmaceuticals has increased from 10% in 2000 to 42% in 2016.
It is the largest and fastest growing fine industry in the modern biopharmaceutical industry.
According to Chlue Research, the total sales of 52 kinds of McAbs approved by FDA were up to 99 billion US dollars in 2016, up 15% from 2015.
McAbs occupy six seats of the world’s top ten best-selling drugs.
The total sales of these six products is up to $56.34 billion 2016
In recent years, the number of newly approved of McAbs showed explosive growth. In 2015 and 2016, 9 and 10 products were adopted respectively.
By the end of September 2017, there were 8 different approved products 2017.
- McAbs Market
- Antineoplastic drugs
- Autoimmune diseases
- Ophthalmic remedy
- PD-1 and PD-L1 McAbs
- McAbs approved by FDA
Download a simple version